Jaka jest cena za Abivax S.A. (ABVX)

Cena za Abivax S.A. (ABVX) wynosi $123.36

Jaka jest kapitalizacja rynkowa dla Abivax S.A. (ABVX)

Kapitalizacja rynkowa dla Abivax S.A. (ABVX) wynosi $10.75B

Abivax S.A. (ABVX) Marża Operacyjna

Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013, dedicated to identifying and refining treatments for various serious conditions, including inflammatory and infectious diseases, as well as cancer. Its primary drug candidate, ABX464, is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's disease, and COVID-19, and is in Phase IIa trials for rheumatoid arthritis. This compound has also successfully completed a Phase IIa study focused on achieving viral remission in HIV patients. Additionally, the company is advancing ABX 196, an immune-enhancing agent, through Phase 1/2 clinical trials for hepatocellular cancer. Beyond these main programs, Abivax is also engaged in research initiatives targeting Dengue fever, influenza, and the respiratory syncytial virus. The company holds significant licensing agreements with esteemed institutions such as the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie.

Rok	Marża operacyjna	Zmień
Za mało danych dla podanych dat.

Rok

Marża operacyjna

Zmień

Za mało danych dla podanych dat.

Firma	Marża operacyjna	Różnica w marży operacyjnej	Kraj
Vertex Pharmaceuticals Incorporated VRTX.US	38.59%	-	US
Argenx SE ARGX.US	28.81%	-	NL
Moderna, Inc. MRNA.US	-149.01%	-	US
CSL Limited CSL.AX	25.72%	-	AU
Lonza Group AG LONN.SW	0.00%	-	CH

Firma

Marża operacyjna

Różnica w marży operacyjnej

Kraj